TLDR Finasteride may reduce prostate cancer risk.
The document discussed the findings of a study that extended observations from the Prostate Cancer Prevention Trial (PCPT) regarding the use of finasteride to reduce prostate cancer risk. This study differed from the PCPT in several ways: it had a smaller sample size, was a retrospective analysis, lacked central pathology review, used a different agent inhibiting both isoforms of 5-alpha-reductase, and involved participants with generally higher PSA values and clinical symptoms of BPH. Despite these differences, like the PCPT, participants underwent annual examinations with digital rectal exams and PSA measurements.
11 citations
,
February 2016 in “Current Medicinal Chemistry” New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
14 citations
,
May 2016 in “Therapeutic advances in urology” Taking tadalafil and finasteride together is safe and effective for treating urinary symptoms and erectile dysfunction in men with enlarged prostates.
54 citations
,
October 2019 in “Cochrane library” Some drugs may reduce prostatitis symptoms short-term with few side effects.
67 citations
,
February 2015 in “Life Sciences” Some plant-based treatments can help with benign prostatic hyperplasia symptoms, but more research is needed to confirm their safety and effectiveness.
15 citations
,
July 2016 in “Urologic Clinics of North America” Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
15 citations
,
December 2006 in “Clinical interventions in aging” 5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.